<h1>Deepak Chem Tech Approves ₹2,500 Crore Project for Bisphenol A Manufacturing</h1>
The Board of Directors of Deepak Chem Tech Limited (DCTL), a wholly owned subsidiary of Deepak Nitrite Limited, has approved a significant project aimed at manufacturing Bisphenol A (BPA). The facility is planned to have a capacity of up to 240 KTA.
The approval includes investment in related greenfield infrastructure and capital expenditure for the manufacturing complex. An approximate investment of ₹2,500 Crores was sanctioned by the DCTL Board, with the final figure expected to be confirmed upon the completion of detailed engineering studies. The project will be financed through an appropriate blend of debt and equity.
Beyond the BPA initiative, the DCTL Board has also greenlit two other major ventures: establishing India's first Polycarbonate resin manufacturing plant, leveraging Trinseo technology and associated asset acquisition, as well as a Phenol & Acetone manufacturing plant.
The addition of the BPA project is set to establish a highly integrated manufacturing platform for Deepak. This integration spans the entire value chain, starting from Cumene through Phenol & Acetone, BPA, Polycarbonate resin, and downstream compounding.
In addition to fulfilling captive requirements necessary for the manufacture of Polycarbonate resins, the new BPA facility will enable Deepak to participate in the rapidly growing Indian market segment dedicated to Bisphenol A, which is used extensively in the production of Epoxy resins.
DEEPAKNTR Stock Price Movement
On Tuesday, shares of Deepak Nitrite Limited edged higher to close at ₹1717.7, climbing 0.36%. The stock traded with a volume of 281,164 shares during the session, hitting a high of ₹1753.5.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.